See more : Tirupati Graphite plc (TGR.L) Income Statement Analysis – Financial Results
Complete financial analysis of Zogenix, Inc. (ZGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Harzone Industry Corp., Ltd (300527.SZ) Income Statement Analysis – Financial Results
- Norway Royal Salmon AS (NRS.OL) Income Statement Analysis – Financial Results
- Rinko Corporation (9355.T) Income Statement Analysis – Financial Results
- Truist Financial Corporation (TFC-PI) Income Statement Analysis – Financial Results
- Definity Financial Corporation (DFY.TO) Income Statement Analysis – Financial Results
Zogenix, Inc. (ZGNX)
About Zogenix, Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.69M | 13.64M | 3.65M | 0.00 | 9.82M | 28.85M | 27.18M | 40.53M | 33.01M | 44.33M | 37.58M | 23.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.83M | 542.00K | 0.00 | 0.00 | 10.73M | 22.47M | 22.70M | 31.88M | 22.48M | 20.85M | 20.50M | 13.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.86M | 13.10M | 3.65M | 0.00 | -908.00K | 6.38M | 4.48M | 8.65M | 10.53M | 23.48M | 17.08M | 9.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 94.08% | 96.03% | 100.00% | 0.00% | -9.25% | 22.12% | 16.49% | 21.35% | 31.89% | 52.96% | 45.45% | 41.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.66M | 138.00M | 115.64M | 100.93M | 67.45M | 41.84M | 27.86M | 18.94M | 12.81M | 21.41M | 33.04M | 28.64M | 21.44M | 33.91M | 24.33M | 4.90M |
| General & Administrative | 0.00 | 99.57M | 33.63M | 23.22M | 21.12M | 20.99M | 22.41M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Selling & Marketing | 0.00 | 0.00 | 27.17M | 15.73M | 4.76M | 6.00M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.52M | 99.57M | 60.79M | 38.95M | 25.89M | 27.00M | 26.35M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Other Expenses | 7.89M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 10.00K |
| Operating Expenses | 299.07M | 241.52M | 176.43M | 139.88M | 93.33M | 68.84M | 54.21M | 107.84M | 62.85M | 70.91M | 93.50M | 79.91M | 35.54M | 45.73M | 29.05M | 6.38M |
| Cost & Expenses | 303.90M | 242.06M | 176.43M | 139.88M | 104.06M | 91.30M | 76.91M | 139.71M | 85.33M | 91.76M | 114.00M | 93.60M | 35.54M | 45.73M | 29.05M | 6.38M |
| Interest Income | 659.00K | 2.89M | 9.80M | 7.17M | 1.09M | 443.00K | 0.00 | 20.00K | 18.00K | 53.00K | 37.00K | 5.00K | 10.00K | 696.00K | 0.00 | 0.00 |
| Interest Expense | 15.28M | 3.76M | 2.00K | 6.00K | 2.64M | 2.83M | 0.00 | 3.09M | 6.61M | 10.31M | 7.64M | 10.01M | 9.19M | 1.72M | 1.35M | 980.00K |
| Depreciation & Amortization | 9.46M | 5.47M | 1.27M | 155.00K | 425.00K | 1.40M | 1.62M | 1.63M | 1.81M | 1.60M | 1.58M | 1.43M | 5.31M | 1.10M | 410.00K | 1.96M |
| EBITDA | -202.58M | -217.58M | -418.23M | -123.75M | -123.75M | -66.43M | 11.86M | 13.39M | -72.44M | -35.47M | -74.68M | -62.11M | -31.39M | -42.75M | -25.92M | -4.42M |
| EBITDA Ratio | -247.98% | -1,594.84% | -11,464.72% | 0.00% | -1,260.03% | -230.25% | 43.65% | 33.03% | -219.44% | -80.02% | -198.75% | -264.96% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -212.03M | -247.72M | -429.82M | -141.18M | -119.94M | -72.69M | -47.73M | -20.04M | -53.19M | -47.43M | -76.42M | -70.16M | -35.54M | -45.73M | -29.05M | -6.38M |
| Operating Income Ratio | -259.56% | -1,815.71% | -11,782.37% | 0.00% | -1,221.22% | -251.94% | -175.58% | -49.44% | -161.13% | -107.00% | -203.39% | -299.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.28M | 20.91M | 10.32M | 17.46M | -6.09M | 3.05M | -9.88M | 28.71M | -27.66M | 50.00K | -7.49M | -3.39M | -1.17M | 1.18M | 1.37M | 980.00K |
| Income Before Tax | -227.31M | -226.81M | -419.50M | -123.72M | -126.02M | -69.63M | -57.61M | 8.67M | -80.86M | -47.38M | -83.91M | -73.55M | -36.71M | -44.55M | -27.68M | -5.40M |
| Income Before Tax Ratio | -278.26% | -1,662.45% | -11,499.53% | 0.00% | -1,283.19% | -241.37% | -211.92% | 21.39% | -244.93% | -106.89% | -223.31% | -313.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 105.00K | -17.43M | 10.32M | 17.47M | -3.44M | -948.00K | -15.90M | 84.00K | -21.05M | 5.00K | -9.00K | 10.00K | 8.02M | 2.90M | 2.72M | 0.00 |
| Net Income | -227.41M | -209.38M | -419.50M | -123.91M | -126.82M | -69.71M | 26.14M | 8.59M | -80.86M | -47.39M | -83.90M | -73.56M | -45.89M | -45.57M | -27.68M | -5.40M |
| Net Income Ratio | -278.39% | -1,534.73% | -11,499.53% | 0.00% | -1,291.28% | -241.62% | 96.18% | 21.19% | -244.93% | -106.90% | -223.29% | -313.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.48 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| EPS Diluted | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.47 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| Weighted Avg Shares Out | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 17.83M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 18.13M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
Zogenix Presents New Data from a Study Highlighting the Impact of Treatment with FINTEPLA® (Fenfluramine) Oral Solution on Dravet Syndrome Patients, Caregivers, and Families at Virtual AAN 2021
EMERYVILLE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers' perspectives on the long-term seizure- and non-seizure-related benefits of...
Zogenix to Participate in the 20th Annual Needham Virtual Healthcare Conference
EMERYVILLE, Calif., April 08, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief...
Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q4 2020 Results - Earnings Call Transcript
Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q4 2020 Results - Earnings Call Transcript
Zogenix to Release Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25
EMERYVILLE, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2020 and host...
Zogenix's FINTEPLA® (Fenfluramine) Oral Solution Now Available in Germany for the Treatment of Seizures in Dravet Syndrome
EMERYVILLE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that FINTEPLA® (fenfluramine) oral solution is now available in Germany for the treatment of seizures associated with Dravet syndrome...
Zogenix Announces Preliminary, Unaudited Fourth Quarter 2020 Net Product Sales
EMERYVILLE, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today reported select preliminary, unaudited financial results for the fourth quarter and full-year 2020. In addition, the Company highlighted...
5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential
After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.
The European Commission Approves Zogenix's FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA® (fenfluramine) oral solution for the treatment of seizures...
Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies
CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ -- Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies,...
Top Stocks To Short Today As Markets Set To Sluggishly End November
As COVID surges to unprecedented levels with additional shutdown measures taking place, markets declined to close what has been a largely strong November. Using our deep learning algorithms, our AI has crunched the data to give you a set of...
Source: https://incomestatements.info
Category: Stock Reports
What were Zogenix’s revenue and net loss in 2021?
Net loss for the second quarter ended June 30, 2021, was $58.9 million, or a net loss of $1.05 per share compared with a net loss of $53.3 million, or a net loss of $0.96 per share, in the second quarter ended June 30, 2020. The Company recorded $32.5 million in revenue for the six months ended June 30, 2021.